Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm.
The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development.
These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells.
Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.
Explore Report Description at: www.psmarketresearch.com/market-an…pipeline-analysis
In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).
The major players for PI3K inhibitors pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: